News
- Time Therapeutics Announces News Release: Preliminary Results of REBRAnD Study, an Investigator-Initiated Clinical Trial for Familial Alzheimer’s Disease by Center for iPS Cell Research and Application (CiRA), Kyoto University; Drug Repositioning of Bromocriptine”
- Exclusive license of “Preventative or therapeutic agent for tauopathy” patent submission by Kyoto University is granted from iPS Academia Japan, Inc. (Kyoto Japan).
- Time Therapeutics Announces News Release: Investigator-Initiated Clinical Trial for Familial Alzheimer’s Disease by Kyoto University
Company
Time Therapeutics Inc., a start-up company based on technology invented at Kyoto University, provides treatments for intractable diseases. Achieving our goal of controlling intractable diseases provides hope for society while assuring sustainable growth of the company.
By developing cures for intractable diseases using iPSC-based drug discovery, Time Therapeutics aims to offer “therapeutics” that generate “time”, perhaps the most irreplaceable item on any patient’s wish list.
Technology
Innovative drug discovery with iPSCs derived from patients for treatment of intractable diseases realizes accurate prediction of medicinal efficacy, precise classification of targeted patients, and appropriate pricing for medicinal compounds. This revolutionary method, called “iPSC-based Drug Discovery: from dish to bedside”, engineers the results of academic research into social benefits.